cephalosporin c has been researched along with me1036 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dalziel, C; Turner, B | 1 |
| Fritsche, TR; Jones, RN; Sader, HS | 1 |
| Hesek, D; Lee, M; Mobashery, S; Vakulenko, SB; Villegas-Estrada, A | 1 |
3 other study(ies) available for cephalosporin c and me1036
| Article | Year |
|---|---|
Interscience conference on antimicrobial agents and chemotherapy--46th annual meeting. Release of data for Dc-159a, and other agents. 27-30 September 2006, San Francisco, CA, USA.
Topics: Animals; Anti-Infective Agents; Carbapenems; Cephalosporins; Drugs, Investigational; Estrogen Receptor Modulators; Fluoroquinolones; Humans; Naphthols; Societies, Scientific; United States | 2006 |
Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Ceftaroline; Cephalosporins; Community-Acquired Infections; Humans; Methicillin Resistance; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus aureus; United States | 2008 |
Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibiotics.
Topics: Acetylglucosamine; Anti-Bacterial Agents; Binding Sites; Biomimetic Materials; Carbapenems; Ceftaroline; Cell Wall; Cephalosporins; Circular Dichroism; Kinetics; Methicillin Resistance; Muramic Acids; Penicillin-Binding Proteins; Peptide Synthases; Peptidoglycan; Protein Conformation; Staphylococcus aureus | 2008 |